Atherogenesis and diabetes: Focus on insulin resistance and hyperinsulinemia;Aterogénesis y diabetes: resistencia a la insulina e hiperinsulinemia

Revista Espanola de Cardiologia

Volumn 65, Issue 4, 2012, Pages 309-313

  Madonna, Rosalinda ^a,b   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; DIABETES MELLITUS; HYPERINSULINEMIA; INSULIN RESISTANCE; REVIEW;

EID: 84858863541     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.11.010     Document Type: Article

References (70)

1. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
2. S.M. Haffner, M.P. Stern, H.P. Hazuda, B.D. Mitchell, and J.K. Patterson Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263 1990 2893 2898
3. F. Cosentino, M. Eto, P. De Paolis, B. Van der Loo, M. Bachschmid, and V. Ullrich High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species Circulation 107 2003 1017 1023
4. G. Basta, A.M. Schmidt, and R. De Caterina Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovasc Res 63 2004 582 592
5. D. Vanuzzo, L. Pilotto, R. Mirolo, and S. Pirelli [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation] G Ital Cardiol (Rome) 9 2008 S6 17S
6. A.K. Gupta, and N.R. Poulter The concept of the metabolic syndrome is it dead yet? J Am Coll Cardiol 56 2010 1355 1356
7. A. Mente, S. Yusuf, S. Islam, M.J. McQueen, S. Tanomsup, and C.L. Onen Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries J Am Coll Cardiol 55 2010 2390 2398
8. A. Tenenbaum, and E.Z. Fisman "The metabolic syndrome. is dead": these reports are an exaggeration Cardiovasc Diabetol 10 2011 11
9. K. Pyorala Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland Diabetes Care 2 1979 131 141
10. R.W. Stout Insulin and atheroma. 20-yr perspective Diabetes Care 13 1990 631 654
11. S. Muntoni, and B. Draznin Effects of chronic hyperinsulinemia in insulin-resistant patients Curr Diab Rep 8 2008 233 238
12. T. Mitsuhashi, K. Hibi, M. Kosuge, S. Morita, N. Komura, and I. Kusama Relation between hyperinsulinemia and nonculprit plaque characteristics in nondiabetic patients with acute coronary syndromes JACC Cardiovasc Imaging 4 2011 392 401
13. G.M. Reaven, H. Chang, H. Ho, C.Y. Jeng, and B.B. Hoffman Lowering of plasma glucose in diabetic rats by antilipolytic agents Am J Physiol 254 1988 E23 E30
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
15. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Ginebra: WHO; 1999.
16. K.L. Cheal, F. Abbasi, C. Lamendola, T. McLaughlin, G.M. Reaven, and E.S. Ford Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome Diabetes 53 2004 1195 1200
17. J.C. Russell, and S.D. Proctor Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis Cardiovasc Pathol 15 2006 318 330
18. C.M. Taniguchi, B. Emanuelli, and C.R. Kahn Critical nodes in signalling pathways: insights into insulin action Nat Rev Mol Cell Biol 7 2006 85 96
19. M. Montagnani, I. Golovchenko, I. Kim, G.Y. Koh, M.L. Goalstone, and A.N. Mundhekar Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells J Biol Chem 277 2002 1794 1799
20. S. Ridray Hyperinsulinemia and smooth muscle cell proliferation Int J Obes Relat Metab Disord 19 Suppl 1 1995 S39 S51
21. I. Golovchenko, M.L. Goalstone, P. Watson, M. Brownlee, and B. Draznin Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells Circ Res 87 2000 746 752
22. R. Madonna, A. Pandolfi, M. Massaro, A. Consoli, and R. De Caterina Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase Diabetologia 47 2004 532 536
23. M. Montagnani, H. Chen, V.A. Barr, and M.J. Quon Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179) J Biol Chem 276 2001 30392 30398
24. K. Cusi, K. Maezono, A. Osman, M. Pendergrass, M.E. Patti, and T. Pratipanawatr Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle J Clin Invest 105 2000 311 320
25. C.C. Wang, M.L. Goalstone, and B. Draznin Molecular mechanisms of insulin resistance that impact cardiovascular biology Diabetes 53 2004 2735 2740
26. M. Combettes-Souverain, and T. Issad Molecular basis of insulin action Diabetes Metab 24 1998 477 489
27. B. Cheatham, and C.R. Kahn Insulin action and the insulin signaling network Endocr Rev 16 1995 117 142
28. E. Araki, M.A. Lipes, M.E. Patti, J.C. Bruning, B. Haag 3rd, and R.S. Johnson Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene Nature 372 1994 186 190
29. M.J. Saad, E. Araki, M. Miralpeix, P.L. Rothenberg, M.F. White, and C.R. Kahn Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance J Clin Invest 90 1992 1839 1849
30. M. Anai, M. Funaki, T. Ogihara, J. Terasaki, K. Inukai, and H. Katagiri Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats Diabetes 47 1998 13 23
31. A. Bertacca, A. Ciccarone, P. Cecchetti, B. Vianello, I. Laurenza, and M. Maffei Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts Metabolism 54 2005 1687 1693
32. R. Madonna, and R. De Caterina Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling Thromb Haemost 101 2009 345 350
33. G.L. Duff, and M.G. Mc The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit J Exp Med 89 1949 611 630
34. A.B. Cruz Jr., D.S. Amatuzio, F. Grande, and L.J. Hay Effect of intra-arterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs Circ Res 9 1961 39 43
35. K.J. Reddy, M. Singh, J.R. Bangit, and R.R. Batsell The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review J Cardiovasc Med (Hagerstown) 11 2010 633 647
36. R. Madonna, M. Massaro, A. Pandolfi, A. Consoli, and R. De Caterina The prominent role of p38 mitogen-activated protein kinase in insulin-mediated enhancement of VCAM-1 expression in endothelial cells Int J Immunopathol Pharmacol 20 2007 539 555
37. R. Madonna, M. Massaro, and R. De Caterina Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells Biochim Biophys Acta 1782 2008 511 516
38. M.I. Cybulsky, K. Iiyama, H. Li, S. Zhu, M. Chen, and M. Iiyama A major role for VCAM-1, but not ICAM-1, in early atherosclerosis J Clin Invest 107 2001 1255 1262
39. R. De Caterina, P. Libby, H.B. Peng, V.J. Thannickal, T.B. Rajavashisth, and M.A. Gimbrone Jr. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines J Clin Invest 96 1995 60 68
40. A. Ruiz-Torres, R. Lozano, J. Melón, and R. Carraro On how insulin may influence ageing and become atherogenic throughout the insulin-like growth factor-1 receptor pathway: in vitro studies with human vascular smooth muscle cells Gerontology 51 2005 225 230
41. P. Zunker, A. Schick, H.C. Buschmann, D. Georgiadis, D.G. Nabavi, and M. Edelmann Hyperinsulinism and cerebral microangiopathy Stroke 27 1996 219 223
42. T. Inukai, R. Matsutomo, K. Tayama, Y. Aso, and Y. Takemura Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus Exp Clin Endocrinol Diabetes 107 1999 40 45
43. K. Sugimoto, M. Baba, T. Suda, M. Yasujima, and S. Yagihashi Peripheral neuropathy and microangiopathy in rats with insulinoma: association with chronic hyperinsulinemia Diabetes Metab Res Rev 19 2003 392 400
44. G. Arcaro, A. Cretti, S. Balzano, A. Lechi, M. Muggeo, and E. Bonora Insulin causes endothelial dysfunction in humans: sites and mechanisms Circulation 105 2002 576 582
45. K.T. Iida, H. Suzuki, H. Sone, H. Shimano, H. Toyoshima, and S. Yatoh Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway Arterioscler Thromb Vasc Biol 22 2002 380 386
46. X.J. Cai, C.A. Lister, R.E. Buckingham, L. Pickavance, J. Wilding, and J.R. Arch Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone Brain Res Mol Brain Res 77 2000 131 137
47. P.A. Sarafidis, and G.L. Bakris Review: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 92 2007 379 385
48. D. Aronson, Z. Bloomgarden, and E.J. Rayfield Potential mechanisms promoting restenosis in diabetic patients J Am Coll Cardiol 27 1996 528 535
49. P.W. Radke, K. Friese, A. Buhr, B. Nagel, L.C. Harland, and A. Kaiser Comparison of coronary restenosis rates in matched patients with versus without diabetes mellitus Am J Cardiol 98 2006 1218 1222
50. R.A. DeFronzo Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 131 1999 281 303
51. R.A. DeFronzo, R.C. Bonadonna, and E. Ferrannini Pathogenesis of NIDDM. A balanced overview Diabetes Care 15 1992 318 368
52. DAI study group The DAI prospective study on macrovascular complications in patients with type 2 diabetes. Characteristics of the study population Ann Ist Super Sanita 37 2001 289 296
53. E. Faglia, F. Favales, and A. Quarantiello Are insulin-treated type 2 subjects at higher risk for foor ulcers? Diabetes Care 22 1999 1379 1380
54. G. Bruno, F. Merletti, P. Boffetta, P. Cavallo-Perin, G. Bargero, and G. Gallone Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus Diabetologia 42 1999 297 301
55. D.J. Angiolillo, E. Bernardo, C. Ramírez, M.A. Costa, M. Sabaté, and P. Jimenez-Quevedo Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 2006 298 304
56. M.J. Garcia, P.M. McNamara, T. Gordon, and W.B. Kannel Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study Diabetes 23 1974 105 111
57. J.C. Kleinman, R.P. Donahue, M.I. Harris, F.F. Finucane, J.H. Madans, and D.B. Brock Mortality among diabetics in a national sample Am J Epidemiol 128 1988 389 401
58. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
59. I. Saito, A.R. Folsom, F.L. Brancati, B.B. Duncan, L.E. Chambless, and P.G. McGovern Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study Ann Intern Med 133 2000 81 91
60. M. Shichiri, H. Kishikawa, Y. Ohkubo, and N. Wake Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients Diabetes Care 23 Suppl 2 2000 B21 B29
61. L. Monnier, C. Colette, E. Mas, F. Michel, J.P. Cristol, and C. Boegner Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy Diabetologia 53 2009 562 571
62. G. Ceolotto, M. Bevilacqua, I. Papparella, E. Baritono, L. Franco, and C. Corvaja Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo Diabetes 53 2004 1344 1351
63. BARI 2D Study Group R.L. Frye, P. August, M.M. Brooks, R.M. Hardison, and S.F. Kelsey A randomized trial of therapies for type 2 diabetes and coronary artery disease New Engl J Med 360 2009 2503 2515
64. R. Madonna, and R. De Caterina Cellular and molecular mechanisms of vascular injury in diabetes - part I: pathways of vascular disease in diabetes Vascul Pharmacol 54 2011 68 74
65. R. Madonna, and R. De Caterina Cellular and molecular mechanisms of vascular injury in diabetes - part II: cellular mechanisms and therapeutic targets Vascul Pharmacol 54 2011 75 79
66. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
67. B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 2004 1647 1653
68. K.K. Ray, S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, and D. Preiss Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765 1772
69. J.S. Skyler, R. Bergenstal, R.O. Bonow, J. Buse, P. Deedwania, and E.A. Gale Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Circulation 119 2009 351 357
70. D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, and T.J. Orchard Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2005 2643 2653